ACADIA PHARMACEUTICALS INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ACADIA PHARMACEUTICALS INC. (ACAD) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $89.62 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-04
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $89.62M, a 69.30% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$18.09M, a 126.17% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $19.33M.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $38.30M.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $92.47M.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$261.92M, a 277.49% decline from fiscal 2015.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $147.57M.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$87.27M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $89.62M 10-Q · filed 2018-05-04 | $71.53M derived: sum of 2 quarters · filed 2018-05-04 | $90.86M derived: sum of 3 quarters · filed 2018-05-04 | $129.16M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-12-31 | -$18.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $1.24M derived: sum of 2 quarters · filed 2018-02-27 | $39.54M derived: sum of 3 quarters · filed 2018-02-27 | $92.47M 10-K · filed 2018-02-27 |
| 2017-09-30 | $19.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $57.63M derived: sum of 2 quarters · filed 2017-11-07 | $110.57M 10-Q · filed 2017-11-07 | $179.71M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-06-30 | $38.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $91.23M 10-Q · filed 2017-08-08 | $160.37M derived: sum of 3 quarters · filed 2018-05-04 | $5.47M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-03-31 | $52.94M 10-Q · filed 2018-05-04 | $122.08M derived: sum of 2 quarters · filed 2018-05-04 | -$32.83M derived: sum of 3 quarters · filed 2018-05-04 | -$40.29M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $69.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$85.77M derived: sum of 2 quarters · filed 2018-02-27 | -$93.23M derived: sum of 3 quarters · filed 2018-02-27 | -$261.92M 10-K · filed 2018-02-27 |
| 2016-09-30 | -$154.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$162.37M derived: sum of 2 quarters · filed 2017-11-07 | -$331.06M 10-Q · filed 2017-11-07 | -$274.34M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | -$7.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$176.16M 10-Q · filed 2017-08-08 | -$119.43M derived: sum of 3 quarters · filed 2018-02-27 | -$111.12M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | -$168.70M 10-Q · filed 2017-05-09 | -$111.97M derived: sum of 2 quarters · filed 2018-02-27 | -$103.66M derived: sum of 3 quarters · filed 2018-02-27 | -$59.60M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $56.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $65.03M derived: sum of 2 quarters · filed 2018-02-27 | $109.10M derived: sum of 3 quarters · filed 2018-02-27 | $147.57M 10-K · filed 2018-02-27 |
| 2015-09-30 | $8.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $52.37M derived: sum of 2 quarters · filed 2016-11-07 | $90.84M 10-Q · filed 2016-11-07 | $131.32M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $44.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $82.54M 10-Q · filed 2016-08-04 | $123.01M derived: sum of 3 quarters · filed 2017-02-28 | $161.89M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $38.47M 10-Q · filed 2016-05-05 | $78.95M derived: sum of 2 quarters · filed 2017-02-28 | $117.82M derived: sum of 3 quarters · filed 2017-02-28 | $50.31M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $40.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $79.35M derived: sum of 2 quarters · filed 2017-02-28 | $11.84M derived: sum of 3 quarters · filed 2017-02-28 | -$87.27M 10-K · filed 2017-02-28 |
| 2014-09-30 | $38.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$28.64M derived: sum of 2 quarters · filed 2015-11-05 | -$127.75M 10-Q · filed 2015-11-05 | -$118.21M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$67.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$166.62M 10-Q · filed 2015-08-06 | -$157.08M derived: sum of 3 quarters · filed 2016-02-29 | -$161.02M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | -$99.11M 10-Q · filed 2015-05-07 | -$89.57M derived: sum of 2 quarters · filed 2016-02-29 | -$93.51M derived: sum of 3 quarters · filed 2016-02-29 | -$192.13M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $9.54M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $5.60M derived: sum of 2 quarters · filed 2016-02-29 | -$93.02M derived: sum of 3 quarters · filed 2016-02-29 | -$126.10M 10-K · filed 2016-02-29 |
| 2013-09-30 | -$3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$102.56M derived: sum of 2 quarters · filed 2014-11-10 | -$135.65M 10-Q · filed 2014-11-10 | -$170.70M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | -$98.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$131.70M 10-Q · filed 2014-08-05 | -$166.76M derived: sum of 3 quarters · filed 2015-02-26 | -$169.50M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | -$33.09M 10-Q · filed 2014-05-06 | -$68.14M derived: sum of 2 quarters · filed 2015-02-26 | -$70.88M derived: sum of 3 quarters · filed 2015-02-26 | |
| 2012-12-31 | -$35.05M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | -$37.80M derived: sum of 2 quarters · filed 2015-02-26 | -$25.53M 10-K · filed 2015-02-26 | |
| 2012-09-30 | -$2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $9.53M 10-Q · filed 2013-11-06 | ||
| 2012-06-30 | $12.27M 10-Q · filed 2013-08-06 | |||
| 2011-12-31 | $5.98M 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |